Contract Notice Detail

Summary Information

Summary Information
6,212.800000 Euro
 
10C0669524 
Aquisição de PANITUMUMAB,IV,20MG/ML;5ML,SOL INJ, ao abrigo do CPA 2023/491, para a ULSASI, para o ano 2024 
Tendering Phase
Awarded
Aquisição de PANITUMUMAB,IV,20MG/ML;5ML,SOL INJ, ao abrigo do CPA 2023/491, para a ULSASI, para o ano 2024 
VortalGOV - Acquisition under a Framework Agreement (via Direct Award) 
Lot NameLot Base PriceExpected Duration
P747 - PANITUMUMAB [20 MG/ML; 5 ML; FRS]-161 (Days)

Object of the Contract

Object of the Contract
Supplies Acquisition 
Ic19 Amadora 2700 Venteira Amadora Lisboa PORTUGAL  
33600000-6 - Pharmaceutical products
 
 
 

Scheduling

Scheduling
7/23/2024 11:44 AM (UTC +1 hour)
 
9/4/2023 11:40 AM (UTC +1 hour)
 
7/25/2024 5:00 PM (UTC +1 hour)
 

Financial Settings

Financial Settings
No 

Contract Documents

Contract Documents
Document NameDescriptionDoc Classification
Anexo II.xlsxAnexo II.xlsxAdditional InformationDownload
Convite 10C0669524.pdfConvite 10C0669524.pdfInstruction to tenderersDownload

Object of contract

No 
No 

Legal, economic, financial and technical information

No 

Questionnaire

Questionnaire
1
Lot Title
P747 - PANITUMUMAB [20 MG/ML; 5 ML; FRS]
Base Price
6 212,800000

1.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
P747 PANITUMUMAB [20 MG/ML; 5 ML; FRS] 20,000000 UN
Buyer Comment: 502942959 | Amgen Biofarmacêutica, Lda. | CPA:2023491/103/0265 | NºAIM:5077144;
TOTAL (The amounts shown do not include VAT)

Evaluation

Evaluation
Vision

Avaliação

Definir modelo de avaliação
Modalidade de avaliação
Método de Avaliação
Divulgar critérios de avaliação

Critérios da Avaliação

1 - P747 - PANITUMUMAB [20 MG/ML; 5 ML; FRS]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.Preço-100%

Normas de desempate

Public Messages

Public Messages
TypeReferenceSubjectDate
No items found...